Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferiprone - Apotex

Next Previous
Drug Profile

Deferiprone - Apotex

Alternative Names: CGP 37391; CMX 001 - CorMedix; CP 020; CP 20; CRMD-001; FERRIPROX; Ferriprox; Ferriprox Oral Solution; Kelfer; L1; Upkanz

Latest Information Update: 04 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Royal Free and University College Medical School
  • Developer Apotex; Centre Hospitalier Univeristaire De Lille; Chiesi; CorMedix
  • Class Antianaemics; Antirheumatics; Pyridones; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Siderosis; Friedreich's ataxia; Iron overload; Neurodegenerative disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase III Pantothenate kinase-associated neurodegeneration
  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease
  • Phase I/II Friedreich's ataxia
  • No development reported HIV infections
  • Discontinued Kidney disorders

Most Recent Events

  • 03 Apr 2023 Registered for Iron overload (Treatment-resistant) in Canada (PO)
  • 15 Oct 2021 Health Canada approves NDA application for deferiprone in Iron overload (in patients with sickle cell disease)
  • 14 Sep 2021 Launched for Iron overload (Combination therapy, Treatment-resistant) in Brazil (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top